Little is known about the changes in calciotropic hormones during puberty and their relationship to bone mass during this critical period for skeletal accretion.
O
steoporosis is a silent disease of pediatric origins that does not manifest until later stages in life (1) . Peak bone mass, defined as the amount of bone mass, is accrued at the end of skeletal maturity between ages 20 and 30 years (2, 3). It is a major determinant of bone mass in later life (4 -6) and a predictor of the risk of developing osteoporosis (5) (6) (7) (8) . Adolescence is a critical time for bone modeling and bone mass accretion. This is reflected by a high bone-modeling activity, with bone formation exceeding resorption during the growth spurt, and until achievement of peak bone mass during the third decade (9) . Over half of adult bone mass is accrued during the pubertal years (2, 10) , and the greatest increments occur between the ages of 11 and 15 years in girls and between 13 and 17 years in boys (3, 11) . Furthermore, boys achieve a greater peak bone mass than girls due to larger bone size, later onset of puberty, and a longer growth spurt (4, 12) . A clear understanding of the determinants of peak bone mass is thus essential.
Bone mass acquisition is a complex process dependent on Tanner pubertal stage and gender (13) , and it seems to be mostly mediated by three hormonal pathways: GH and IGF-1, sex hormones, and possibly the vitamin D axis. Calciotropic hormones have an important role in mineral metabolism and bone mineralization. 1,25-Dihydroxyvitamin D is essential for intestinal absorption of calcium and phosphorus, two key components of hydroxyapatite and bone mineralization (14) . 1,25-Dihydroxyvitamin D increments during puberty would theoretically optimize the calcium and phosphorus economy and thus enhance bone mineral accretion during this critical time window for bone mass accrual. The few studies evaluating this hormone in this age group have led to contradicting results (15) (16) (17) (18) (19) (20) (21) . Furthermore, the relationship between calciotropic hormones, bone markers, and bone density in children and adolescents, overall and by gender, remains largely unknown.
In this study, we therefore explored changes in calciotropic hormones, IGF-1, body composition parameters, and bone mass across pubertal changes and investigated whether their patterns and associations vary by gender.
Subjects and Methods
Post hoc exploratory analyses based on existing data were collected at study entry from a vitamin D randomized, double-blind, placebo-controlled trial evaluating the efficacy of vitamin D supplementation on skeletal health (22) . The trial enrolled healthy children and adolescents ages 10 to 17 years between December 2001 and June 2002. Recruitment took place in four schools from the greater Beirut area to ensure balanced representation geographically and socioeconomically. The study was approved by the Institutional Review Board of the American University of Beirut, and an assent and informed consent were obtained from all study participants and their parents, respectively. Vitamin D replacement had a positive impact on musculoskeletal parameters in girls, especially during the premenarcheal period (22) . Only baseline data were considered for our analyses, in view of the interventional nature of the trial.
Subjects
The primary trial was conducted on 363 healthy school children (179 girls and 184 boys), mean age 13 Ϯ 2 years, but our analyses are based on 335 children (166 girls and 169 boys) due to 1,25-dihydroxyvitamin D data missing from 28 subjects. The subjects were included in the study if they were considered to be healthy, did not suffer from any conditions known to affect bone metabolism, and had a normal physical examination. At study entry, all subjects had normal serum calcium, phosphorus, and alkaline phosphatase levels for their age. Excluded were the children with diseases known to affect bone metabolism, including renal disease, liver disease, chronic diarrhea, and gastric and bowel surgery. Also excluded were children on high-dose vitamins within 6 months of study entry, as well as those on drugs known to affect bone and mineral metabolism (22) . Subjects who did not have 1,25-dihydroxyvitamin D levels measured did not differ from the cohort in most of the baseline clinical and anthropometric characteristics but had few different baseline studies: higher 25-hydroxyvitamin D [25(OH)D] and sun exposure, higher baseline IGF-1, and lower phosphorus and Alkaline Phosphatase (albeit still in the normal range).
Data collection

Clinical data
Subjects enrolled in the study had a baseline physical examination, including height, weight, and Tanner stages (23). Standing height was measured in triplicate in centimeters to the nearest 1 mm using a wall stadiometer, and the average was used in the analyses. Weight was recorded in kilograms, to the nearest 0.5 kg, with the subjects wearing light clothes without shoes using a standard clinical balance. Mean height and weight were rounded to the nearest integer. Pubertal status was determined by the physicians of the study (H.K., M.N., or M.C.) using breast and pubic hair stages in girls or testicular and pubic hair stages in boys, according to the established criteria of Tanner (23) .
Calcium intake, exercise, sun exposure, and history of fractures were assessed by a questionnaire at baseline as previously described (22, 24) .
Biochemical data
Serum calcium, phosphorus, and alkaline phosphatase were measured at baseline by standard calorimetric methods using the Hitachi 912 analyzer (Roche Diagnostics). Blood for hormonal studies was stored as serum at Ϫ70°C. Serum 25(OH)D was assessed by RIA by a competitive protein binding assay using the Incstar Kit (Diasorin), with intra-and interassay coefficients of variation (CVs) Ͻ 13% at a serum concentration of 47 ng/mL, and the normal range as reported in the kit insert was 10 -60 ng/mL. Serum 1,25-dihydroxyvitamin D was measured by RIA using the IDS kit with intra-and interassay CVs Ͻ 10% at serum concentrations between 10 and 100 pg/mL (IDS Immuno-Diagnostic Systems). Serum osteocalcin was measured by RIA using the OSTEO-RIACT kit (CIS Bio International) with intra-and interassay CVs Ͻ 10% at serum concentrations between 5.5 and 180 ng/mL. Serum IGF-1 was measured by RIA using the IGF-1-RIACT kit (CIS Bio International) with intra-and interassay CVs Ͻ 8% at serum concentrations between 30 and 350 ng/mL. Serum PTH was measured by using the ELSA-PTH (CIS Bio International) with intra-and interassay CVs Ͻ 7.5% at serum concentrations between 15 and 200 ng/mL.
Bone parameters
Areal bone mineral density (BMD, in grams per square centimeter) and bone mineral content (BMC, in grams) of the anteroposterior lumbar spine (L1-L4), the left femur (total hip, femoral neck, and trochanter), and subtotal BMD, BMC, and body composition were measured at baseline by a dual-energy x-ray absorptiometry using a Hologic 4500A densitometer (software version 11.2:3; Hologic Inc.) in the fast array mode. Because inclusion of the head BMD in the calculation of total body BMD may lower the predictive value of some parameters for this variable, subtotal body measurements, excluding the head, were used in the analyses (25) . In our center, the mean Ϯ SD precision of the BMD measurements, expressed as the CV, for 280 sameday duplicate scans performed during the study duration was Ͻ 
Statistical analysis
Continuous and categorical data were expressed as mean Ϯ SD (except when mentioned otherwise) and counts and percentages, respectively. Group comparisons were tested using 2 tests for categorical variables and independent t tests or ANOVA, as applicable, for continuous variables. Two-way ANOVA was performed to examine the effect of gender and Tanner hair stages on the different biochemical and hormone levels and bone parameters. Correlation analyses were conducted between hormonal and bone mass parameters by Tanner stages. Pearson correlation coefficient and partial correlations were also reported after adjustment. Analyses were performed evaluating girls in premenarche (Tanner stages I and II) and postmenarche (stages III, IV, and V) and in boys in early puberty defined as stages I-III and late puberty as stages III and IV (26) . For all analyses, we used Tanner breast and testicles for staging because these are more reflective of the actual pubertal stage, with the exception of one-way and two-way ANOVA. Because the number of subjects per Tanner stage was small with such staging, we used Tanner hair staging instead to ensure a more even distribution within cells and allow for more robust analyses comparing the two genders across the five Tanner stages. Repeating the identical analyses using Tanner breast and testicles essentially leads to the same results, for both one-way and two-way ANOVA (see Results).
Multivariate hierarchical linear regression modeling was performed to study the relationship between the different bone parameters as outcome and the most consistent predictors in our study, namely IGF-1, and body composition variables. The predictors were entered by blocks, where the first block included IGF-1 and the second block included subtotal lean mass, to assess how much of the effect of IGF-1 on bone mass may have been mediated by lean mass. Therefore, ⌬R 2 represents the incremental increase in the explained variance of the dependent variable upon introducing additional predictors to the model. We also implemented a model entering fat mass as a third block. This multivariate hierarchical linear regression modeling was stratified by early pubertal stages using Tanner breasts I and II in girls and Tanner testicular I, II, and III in boys. P values Ͻ .05 were considered statistically significant and were not corrected for multiple testing because these were considered exploratory post hoc analyses. Analyses were performed using SPSS version 22.0 software (IBM) and SigmaPlot 12.0 (Systat Software Inc.).
Results
Study subjects and baseline characteristics
Clinical characteristics of the study group are shown in Tables 1 and 2 . The mean age for all participants was 13 Ϯ 2 years, with no difference in age between genders. Boys were taller and had a significantly higher body mass index, weekly sun exposure, and daily calcium intake and were more likely to exercise than girls (Table 1) . A significantly higher proportion of boys were in early puberty (Tanner I and II); in contrast, a larger proportion of girls were in more advanced pubertal stages (III to V). Boys had higher serum calcium, phosphorus, 25(OH)D, osteocalcin, and alkaline phosphatase and a lower IGF-1 level compared to girls (Table 1) . Eighty percent of boys and 85% of girls had a serum 25(OH)D level below 20 ng/mL. Lean mass and bone mass parameters at the hip and femoral neck were higher in boys than girls, whereas bone mass parameters were higher at the lumbar spine in girls (Table 2) .
Biochemical variables, calciotropic hormones, and bone mass parameters across pubertal stages by Tanner hair within gender There were no significant differences in serum calcium, 1,25-dihydroxyvitamin D, or 25(OH)D levels across Tanner stages in both genders (Figure 1 and Supplemental Table 1 ) (P Ͼ .05). Conversely, PTH, IGF-1, osteocalcin, phosphorus, and alkaline phosphatase changed substantially across pubertal stages with differing patterns by gender, peaking for the most part at Tanner stage II in girls and stage III in boys (Figure 1 ). In boys, PTH levels rose and were highest at Tanner stage III at 25.7 pg/mL, with progressively lower values thereafter, whereas in girls, the highest level was noted at Tanner I at 23.1 pg/mL ( Figure  1 and Supplemental Table 1 ). The largest increment for most variables was noted between Tanner stages I and II for girls and stages II and III for boys (Supplemental Table  1 ). There was a significant difference in height and weight across Tanner stages in boys and girls, being highest at stage V (Supplemental Table 1 ). Similarly, there were also substantial increments in bone mass variables (area, BMC, BMD; P Ͻ .005 ) (Figure 2 and Supplemental Table 2 ) and body composition parameters (fat mass and lean mass) (Supplemental Figure 1 and Supplemental Table 2 ) across Tanner stages in both genders. Repeating the same analyses for both one-way and two-way ANOVA using Tanner breast and testicles for all of the above analyses essentially leads to the same results.
Biochemical variables, hormones, and bone mass parameters across pubertal stages by Tanner hair between genders
A significantly different pattern of change was found in 1,25-dihydroxyvitamin D, IGF-1, osteocalcin, alkaline phosphatase, and phosphorus levels between genders (Figure 1) . Bone area, BMC, and BMD were consistently higher at the hip and total body in boys compared to girls, especially in late Tanner stages (Figure 2 ). Similarly, a significantly higher lean mass was noted in boys compared to girls at all Tanner stages (Supplemental Figure 1) . Fat mass increased with Tanner stages in both genders, but no gender differences were recorded (Supplemental Figure 1) .
Association between calciotropic hormones and bone mass parameters in early vs late puberty
There were no significant correlations between baseline 25(OH)D levels with BMD at any skeletal site in early (I, II) and late (III, IV, V) Tanner stages in girls or in early (I, II, III) Tanner stages in boys. There was a weak inverse correlation between 25(OH)D level and BMD at the total hip (BMC and BMD), femoral neck (BMD), and subtotal A weak but significant correlation (R ϭ 0.21-0.31) was found between 1,25-dihydroxyvitamin D and a few bone mass parameters. This association was noted at the femoral neck area in early Tanner stages (I, II) for girls and at the spine (area and BMC) in early Tanner stages (I, II, III) for boys (Supplemental Table 3 ). PTH was not found to have any significant association with bone mass parameters in early Tanner stages, both in boys and girls, whereas negative correlations were noted in late Tanner stages (III, IV, and V) at the spine, hip, femoral neck, and subtotal body in girls (Rϭ Ϫ0.21 to Ϫ0.45; P Ͻ .005) and with femoral neck BMD at late Tanner stages (IV and V) in boys (R ϭ Ϫ0.32; P ϭ .03).
Unadjusted association between IGF-1, body composition, and bone mass parameters
We noted significant associations between IGF-1 and bone mass parameters across Tanner stages (Table 3 ; R ϭ 0.25- 0.59), and these were for the most part nonexistent in later Tanner stages in both genders, with few exceptions (Table 3) .
Both lean mass and fat mass correlated positively with multiple bone parameters at early and late Tanner stages and for both genders. In early Tanner stages, lean mass correlated at all skeletal sites, both in girls (R ϭ 0.58 -0.94; P Ͻ .001) and boys (R ϭ 0.51-0.94; P Ͻ .001). Similarly, in late Tanner stages, lean mass correlated with bone parameters at all sites in girls (R ϭ 0.45-0.84; P Ͻ .001) and boys (R ϭ 0.34 -0.88; P Ͻ .03). Cross-sectional representation of bone mass parameters across Tanner hair stages by gender (mean Ϯ SE). ANOVA was implemented for within-gender analyses and were all significant (P Ͻ .001). Gender differences in bone parameters across Tanner hair stages were compared using two-way ANOVA (P values are displayed within figures). The temporal profile by Tanner stages differed significantly between genders for all parameters, with the exception of calcium and 25(OH)D. press.endocrine.org/journal/jcem
Fat mass also correlated with bone mass in girls and boys during early and late Tanner stages, with few exceptions (range for R ϭ 0.22-0.67; P Ͻ .01 for girls; and R ϭ 0.33-0.71; P Ͻ .02 in boys).
Adjusted associations between IGF-1 and bone mass parameters
Positive associations between IGF-1 and bone parameters, adjusted for lean mass, persisted in early Tanner Table 4) . Positive associations between IGF-1 and bone parameters, adjusted for fat mass, persisted in early Tanner stages in both genders (R ϭ 0.27-0.61; P Ͻ .005) (data not shown).
Multivariate linear regression
Supplemental Tables 4 and 5 detail the multivariate linear regression entering IGF-1, followed by lean mass, as predictors of the different skeletal parameters for girls and boys, respectively. In girls, IGF-1 accounted for 18 -44% of variance in bone mass parameters in early Tanner stages (Supplemental Table 4 ), and lean mass independently accounted for 20 -57% of such variance after adjusting for IGF-1, depending on the skeletal site. In boys, IGF-1 accounted for 4 -24% of bone mass parameters in early Tanner stages (Supplemental Table 5 ). Lean mass independently accounted for 18 -67% of variance in bone parameters, after adjusting for IGF-1, depending on the skeletal site. We have also performed additional regression analyses using the hierarchical modeling approach, but entering lean mass as the first block and then IGF-1. Lean mass is clearly the major contributor to the explained variation in bone mass parameters in both genders, where the proportion of variance accounted for by lean mass (R  2 ) ranged between 36 and 91% in girls, with nonsignificant additional minor changes added upon introducing IGF-1 (data not shown). Similarly, in boys, lean mass was also the major contributor to the explained variance in bone parameters where R 2 varied between 24 and 89%, with no additional significant increase in the explained variance upon introducing IGF-1. Additional analyses, entering fat mass in the multivariate model after lean mass, revealed that lean mass in the early Tanner stages in girls contributed more than fat mass to the variance in the bone parameters. Indeed, lean mass still accounted for 20 -57% of such variance, after adjusting for IGF-1, whereas fat mass lost its significance at most skeletal sites (with the exception of area and BMC of the lumbar spine and total hip) and only accounted for 4 -12% of such variance (data not shown).
Similar observations were seen in early Tanner stages in boys. Lean mass accounted for 18 -67% of the explained variance in bone parameters (Supplemental Table 5 ), whereas fat mass lost its significance at most skeletal sites and only accounted for 0.7-8.7% of the total explained variance in bone mass parameters at the area and BMC of the lumbar spine and total hip, in addition to the area of the femoral neck and subtotal body (data not shown).
We have also performed additional regression analyses using the hierarchical modeling approach, entering lean mass as the first block and then IGF-1. As shown in Supplemental Table 6 for girls and Supplemental Table 7 for boys, the proportion of variance in bone mass accounted for by lean mass (R 2 ) ranged for the most part between 36 and 91% in girls, with nonsignificant additional changes after introducing IGF-1. Similarly, in boys, the proportion of the variance in bone parameters accounted for by lean mass varied between 24 to 89%, with no additional significant increase upon introducing IGF-1.
Discussion
In this cohort of apparently healthy school children with hypovitaminosis D, we demonstrate clear changes in IGF-1, PTH, phosphate, osteocalcin, and alkaline phosphatase, but not vitamin D metabolites, across Tanner stages in both genders. These mostly peak in Tanner stage II in girls and stage III in boys and tended to accompany in their temporal profile the most substantial increments in bone mass. 1,25-Dihydroxyvitamin D peaked in Tanner stage II in girls and stage III in boys but was not a consistent predictor of bone mass in adolescents. The strongest and most consistent correlations were noted between IGF-1 and lean mass, with bone mass parameters at early pubertal stages in both genders, both in unadjusted and adjusted analyses. The effect of IGF-1 was in large part explained by changes in lean mass.
The increments in 1,25-dihydroxyvitamin D in early to midpuberty have been previously described in healthy children, but such findings were not consistent across studies (15) (16) (17) (18) (19) (20) (21) . Levels have been reported as high as 92 and 112 pg/mL in one study in girls (15) , and median values of 68 -72 pg/mL were reported in another publication (21) . Such increments could be in anticipation of the growth spurt, bone mass increments, and mineralization during adolescence. A weak association between 1,25-dihydroxyvitamin D and bone mass was noted in girls at the femoral neck area during Tanner stages I and II (mean age, 10 -11 years) and in boys at the spine area and BMC during Tanner stages I, II, and III (mean age, 12-14 years). This correlation in early puberty occurred before the highest increment in bone mass for both genders. An increase in 1,25-dihydroxyvitamin D at this age could be in anticipation for the substantial increase in bone mass during puberty. Few studies in adolescents and children have demonstrated a higher 1,25-dihydroxyvitamin D level with age (15) (16) (17) and with pubertal stages (21) , but these findings were not consistent (18, 19) . Ilich et al (21) had reported in a cross-sectional study that the highest 1,25- press.endocrine.org/journal/jcemdihydroxyvitamin D occurred during the late stages of sexual maturation index between 3 and 4 (ages 13 and 14 years) and correlated to greater bone mass accumulation at the forearm and total body. These authors found no association with bone mass in the longitudinal part of the study; however, it became significant when authors evaluated the rate of change in bone variables over time (21) . A more recent longitudinal study evaluated the association between PTH, 1,25-dihydroxyvitamin D, and bone growth in 594 subjects ages 5-21 years, cross-sectionally and longitudinally in a subset (n ϭ 145) between 1,25-dihydroxyvitamin D and BMC gain and an increase in bone markers (27) . The investigators reported greater bone mass accrual in subjects with higher PTH and 1,25-dihydroxyvitamin D; however, the number of subjects evaluated during puberty is anticipated to be low. In addition, neither of the two studies described above investigated the temporal profile of other key hormones across puberty, such as the IGF-1 axis.
There was a significant change for other biochemical parameters and hormones in both genders, including IGF-1, PTH, alkaline phosphatase, and osteocalcin. These hormones reflect or play a role in bone formation and appear to directly precede or coincide with the significant increments in bone mass during puberty. We noticed a biphasic pattern change in these hormones, with the greatest increments occurring earlier in girls (between Tanner stages I and II) than in boys (between stages II and III). The findings for PTH in our study are similar to those noted by DeBoer et al (27) , although they occurred slightly earlier in our study. PTH levels were negatively associated with bone mass in both genders during more advanced pubertal stages, findings similar to what was noted by Abrams et al (14) marginally at the spine but not with other skeletal sites, but that contrast with the positive associations reported by DeBoer et al (27) . Changes in biochemical markers peaking at Tanner stage II in girls and stage III in boys are representative of the well-described earlier growth spurt and sexual maturation in girls. Russel et al (28) had previously reported on the strong association between GH and pubertal changes in bone metabolism, peaking in midpuberty and correlating with bone remodeling in both genders. We also show a clear and strong association between IGF-1 and bone parameters across Tanner stages. The association between IGF-1 and bone mass parameter was stronger with bone area and BMC than with BMD, underscoring the effect of growth on these parameters that reflect bone size. This association was evident in early Tanner stages for both genders, and the decrease after lean mass adjustment indicates that the effect of IGF-1 on bone mass may in part be mediated by changes in lean mass. Breen et al (29) investigated 76 girls (mean age, 6.4 Ϯ 1.6 years) and reported strong associations between IGF-1 and bone mass accrual (R ϭ 0.9) at several skeletal sites. Similarly, Xu et al (30) reported that IGF-1 promoted bone apposition in a 7-year longitudinal study of 258 healthy girls, age 11.2 years. A recent cross-sectional study reported a positive association between IGF-1 and 1,25-dihydroxyvitamin D at the level of the duodenum, with both increasing to meet the calcium economy during this critical period of growth spurt (31) . On multivariate analysis, IGF-1 mass was a strong predictor of bone mass, and lean mass seems to play an equal if not greater role in bone mass accretion. Indeed, lean mass was found to be responsible for up to 57% of bone mass in girls and 67% in boys after adjustment for IGF-1. Conversely, lean mass prevailed when entered first before IGF-1. We had previously dissected the effect of lean mass and fat mass on BMC in this study group and demonstrated lean mass to be the most substantial predictor (32) . In this study, similar findings are demonstrated when analyses are conducted, including IGF-1 after lean mass in the model, and they suggest that the effect of lean mass is in part, but not totally, explained by IGF-1.
The continued increase in bone mass until Tanner stage V and beyond may be due to the effect of sex steroids during the more mature Tanner stages (33). Our findings are almost identical to another study investigating the relationship between gonadal steroids, bone formation markers, and growth parameters in 174 healthy pubertal children from both genders (33) . Osteocalcin, a marker of bone formation, had a similar pattern of change to PTH and IGF-1, with the largest increments between Tanner stages I and II for girls and stages II and III for boys, but osteocalcin came down in later Tanner stages in parallel to PTH and in contrast to IGF-1. In the HELENA crosssectional study of 345 adolescents, Gracia-Marco et al (34) demonstrated a significant decrease in bone markers, whereas sexual maturation increased in both genders. However, Yilmaz et al (33) demonstrated that osteocalcin did not change across pubertal stages.
Finally, we noted a significant difference in 1,25-dihydroxyvitamin D, IGF-1, osteocalcin, phosphorus, alkaline phosphatase, and bone mass parameters between genders across the Tanner stages. Boys achieved a higher bone mass than girls, a finding possibly explained by larger bone size and lean mass, and the largest increments occurred consistently later in boys than in girls due to boys' known delay in sexual maturation.
Our study has a few limitations, including its crosssectional nature and the fact that it is based on post hoc exploratory analyses, allowing an evaluation of associations but not causality. We did not measure sex steroids, important predictors of muscle and skeletal development, due to budgetary constraints. Our analyses may have been underpowered in analyses by Tanner stages, but we tried to address this shortcoming by breaking down puberty into early vs late puberty. Finally, some of the significant P values may have been due to chance in view of the multiple tests performed, and they were not corrected for multiple testing because we considered these analyses hypothesis generating. Nevertheless, our study, has several strengths. Although it is not population-based, it provides equal representation by gender and socioeconomic status. It includes students of both genders from high and low socioeconomic status schools in the greater Beirut area, an area that captures 20 -25% of the total Lebanese population. Moreover, it is unique in concomitantly exploring the relationship between 1,25-dihydroxyvitamin D, PTH, and IGF-1 with bone mass by Tanner stages, within and between genders. Finally, our study also investigated lean mass and fat mass and adjusted for these important predictors, thus allowing for a more global understanding of physiological determinants of bone mass accretion in adolescents.
In conclusion, we reported changes in serum phosphorus, PTH, alkaline phosphatase, osteocalcin, and IGF-1, but not in calcium, 25(OH)D, or 1,25-dihydroxyvitamin D across puberty. 1,25-Dihydroxyvitamin D level correlations with bone mass in early puberty were weak and were not consistent across skeletal sites. IGF-1 was a robust predictor of bone mass in both genders in early puberty, as was lean mass, and the positive impact of IGF-1 may in large part be explained by lean mass. These observations should be explored further in larger cohorts with longitudinal follow-up to resolve contradicting results in the literature and gain insight regarding the relative contribution of key hormonal physiological pathways, namely IGF-1, calciotropic hormones, and sex steroids, and their respective temporal and hierarchal relevance to lean mass and bone mass increments during childhood and adolescence.
